About Xperiome™

Pete Chan

Head of research & analysis

Pete Chan, head of research & analysis, is responsible for longitudinal data projects and authoring publications based on insights from Raremark’s patient communities.

Neil Rotherham

Chairman

Neil originally qualified as a physician, before moving into the pharmaceutical industry in drug development. In 1993 he set up his first business, ClinPhone plc, that he grew from start-up to floated company. Since leaving ClinPhone, he has been serially involved in a variety of technology and services business as an executive, board member and investor. His focus is on business strategy, institutional fundraising and creating shareholder value.

Jeremy Edwards

Chief executive officer

For nearly 25 years, Jeremy has been focused on aiding the biopharmaceutical and health sciences industry in the development of key compounds and new therapies. He has been instrumental in introducing small, European-based eClinical organizations to the US Market, creating new verticals, growing operations, and increasing revenue. His diverse background includes executive leadership positions across the clinical development continuum; from full-service CROs, to highly specialized imaging modalities, to niche patient-focused service providers. By stretching the way we think about study conduct, both pre and post-approval, and driven by innovative technologies, Jeremy focuses on helping people succeed by addressing unmet needs, in an unconventional, innovative way.

Nicki Grundy

Chief financial officer

Nicki Grundy, chief financial officer, has a proven track record of financial and operational success having qualified with PWC and worked across several sectors including utilities, education, life sciences, and technology, and in firms ranging from startups to multinational companies. At Xperiome, Nicki is in charge of our financial vision, strategic financial planning, and financial compliance.

Dale Jessop

Chief technical officer

Dale Jessop, chief technical officer, brings a wealth of expertise and two decades worth of experience to the business. He moved into the pharma industry in 2012, joining eCOA pioneer Exco InTouch, where as CTO, he helped the company grow from 35 to around 180 people. In the last few years, he has been part of a healthtech IPO on the London Stock Exchange and has built an eConsent platform for clinical research, which was acquired in September 2020. At Xperiome, Dale is responsible for developing and directing our data-driven tech strategy as well as expanding and refining our software offerings.

Alex Garner

Chief operating officer

Alex Garner, chief operating officer, has been with the company since its inception. He discovered a passion for building healthtech products during his time at the NHS where he spent five years implementing and designing digital applications. Along with a master’s degree in business management and innovation, Alex is a firm believer in the principles of user-centered design and constant learning. At Xperiome, Alex is in charge of managing and implementing our operational strategy, as well as driving extensive and sustainable growth.

Caroline O’Connor

Chief commercial officer

Caroline O’Connor, chief commercial officer, has a passion for patient-centric healthcare, along with a wealth of experience in commercial roles in life sciences technology and services. Over the last decade, her focus has been on eClinical technology, combined with establishing value and driving revenue growth from RWE and Digital Patient Support Programs in the post-approval setting. At Xperiome, Caroline leads our commercial strategy and plays a key role in growing our presence in the pharma industry.

Julie Walters

Founder

Julie Walters, founder, is the driving force behind Raremark. She has a first-class degree in molecular genetics from King’s College London and a background in popular journalism, before combining her skills to drive change in health. She is an entrepreneur by nature and believes in harnessing the power of families affected by rare disease. She is the winner of multiple awards, including Female Entrepreneur of the Year at the UK’s 2017 Enterprise Awards.

Peter Coë

Co-founder

Peter Coë, co-founder and client services director, has been with the company from the outset. He has more than three decades’ experience in communications, originally as a reporter, editor and presenter for TV-am, the BBC and Sky News, and has led complex healthcare programmes in multiple languages and countries since 2007.

Pete Chan

Head of research & analysis

Pete Chan, head of research & analysis, is responsible for longitudinal data projects and authoring publications based on insights from Raremark’s patient communities.

Neil Rotherham

Chairman

Neil originally qualified as a physician, before moving into the pharmaceutical industry in drug development. In 1993 he set up his first business, ClinPhone plc, that he grew from start-up to floated company. Since leaving ClinPhone, he has been serially involved in a variety of technology and services business as an executive, board member and investor. His focus is on business strategy, institutional fundraising and creating shareholder value.

Jeremy Edwards

Chief executive officer

For nearly 25 years, Jeremy has been focused on aiding the biopharmaceutical and health sciences industry in the development of key compounds and new therapies. He has been instrumental in introducing small, European-based eClinical organizations to the US Market, creating new verticals, growing operations, and increasing revenue. His diverse background includes executive leadership positions across the clinical development continuum; from full-service CROs, to highly specialized imaging modalities, to niche patient-focused service providers. By stretching the way we think about study conduct, both pre and post-approval, and driven by innovative technologies, Jeremy focuses on helping people succeed by addressing unmet needs, in an unconventional, innovative way.

Nicki Grundy

Chief financial officer

Nicki Grundy, chief financial officer, has a proven track record of financial and operational success having qualified with PWC and worked across several sectors including utilities, education, life sciences, and technology, and in firms ranging from startups to multinational companies. At Xperiome, Nicki is in charge of our financial vision, strategic financial planning, and financial compliance.

Dale Jessop

Chief technical officer

Dale Jessop, chief technical officer, brings a wealth of expertise and two decades worth of experience to the business. He moved into the pharma industry in 2012, joining eCOA pioneer Exco InTouch, where as CTO, he helped the company grow from 35 to around 180 people. In the last few years, he has been part of a healthtech IPO on the London Stock Exchange and has built an eConsent platform for clinical research, which was acquired in September 2020. At Xperiome, Dale is responsible for developing and directing our data-driven tech strategy as well as expanding and refining our software offerings.

Alex Garner

Chief operating officer

Alex Garner, chief operating officer, has been with the company since its inception. He discovered a passion for building healthtech products during his time at the NHS where he spent five years implementing and designing digital applications. Along with a master’s degree in business management and innovation, Alex is a firm believer in the principles of user-centered design and constant learning. At Xperiome, Alex is in charge of managing and implementing our operational strategy, as well as driving extensive and sustainable growth.

Caroline O’Connor

Chief commercial officer

Caroline O’Connor, chief commercial officer, has a passion for patient-centric healthcare, along with a wealth of experience in commercial roles in life sciences technology and services. Over the last decade, her focus has been on eClinical technology, combined with establishing value and driving revenue growth from RWE and Digital Patient Support Programs in the post-approval setting. At Xperiome, Caroline leads our commercial strategy and plays a key role in growing our presence in the pharma industry.

Julie Walters

Founder

Julie Walters, founder, is the driving force behind Raremark. She has a first-class degree in molecular genetics from King’s College London and a background in popular journalism, before combining her skills to drive change in health. She is an entrepreneur by nature and believes in harnessing the power of families affected by rare disease. She is the winner of multiple awards, including Female Entrepreneur of the Year at the UK’s 2017 Enterprise Awards.

Peter Coë

Co-founder

Peter Coë, co-founder and client services director, has been with the company from the outset. He has more than three decades’ experience in communications, originally as a reporter, editor and presenter for TV-am, the BBC and Sky News, and has led complex healthcare programmes in multiple languages and countries since 2007.

Pete Chan

Head of research & analysis

Pete Chan, head of research & analysis, is responsible for longitudinal data projects and authoring publications based on insights from Raremark’s patient communities.

About Xperiome™

Meet the team behind Xperiome

Pete Chan

Neil Rotherham

Jeremy Edwards

Nicki Grundy

Dale Jessop

Alex Garner

Caroline O’Connor

Julie Walters

Peter Coë

Pete Chan

Neil Rotherham

Jeremy Edwards

Nicki Grundy

Dale Jessop

Alex Garner

Caroline O’Connor

Julie Walters

Peter Coë

Pete Chan

Latest news

About Raremark

Our partners and affiliations

About Xperiome™

Meet the team behind Xperiome

Neil Rotherham

Latest news

About Raremark

Our partners and affiliations

Join the team